30
Participants
Start Date
August 22, 2019
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
Abatacept
All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Columbia University Irving Medical Center, New York
Oishei Children's Hospital, Buffalo
Nemours/Alfred I. DuPont Hospital for Children, Wilmington
Childrens Healthcare of Atlanta, Atlanta
Children's of Alabama, Birmingham
University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders, Jackson
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Dana-Farber Cancer Institute, Boston
Hackensack Meridian Health, Hackensack
Collaborators (1)
Thrasher Research Fund
OTHER
Sickle Cell Transplant Advocacy & Research Alliance (STAR)
UNKNOWN
Aflac Cancer and Blood Disorders Center
UNKNOWN
Bristol-Myers Squibb
INDUSTRY
Emory University
OTHER